Skip to main content
. 2020 Dec;98(6):648–657. doi: 10.1124/molpharm.120.000131

Fig. 4.

Fig. 4.

Interactions of JMS-053 and other anticancer drugs with domain IB amino acids in HSA. (A) Binding environment of JMS-053 and teniposide. (B) Binding environment of JMS-053 and idarubicin.